Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELF3 antisense RNA 1 (ELF3-AS1)
- Target
- ELF3-AS1
- Molecular classification
- Long non-coding RNA, Non-coding RNA, Other
01
Overview
ELF3 antisense RNA 1 (ELF3-AS1) is a human long non-coding RNA (lncRNA) transcribed from the antisense strand of the ELF3 locus. It does not encode a protein but acts as a regulatory RNA implicated in oncogenic processes. ELF3-AS1 is upregulated in several cancers, including osteosarcoma and bladder cancer, where it promotes tumor cell proliferation and disease progression. Mechanistically, ELF3-AS1 upregulates the oncogenic transcription factor KLF12 by promoting methylation and downregulation of the tumor suppressor miR-205. Its aberrant expression is correlated with higher cancer stage and more aggressive phenotype, supporting its candidacy as a potential diagnostic biomarker and experimental therapeutic target in oncology.
- Other names
- SCAT7S-phase cancer-associated transcript 7ENST00000415582NR_146472.1
02
Mechanism of action
Not applicable for drugs, but mechanistically, ELF3-AS1 appears to promote cancer cell proliferation by: Upregulating Kruppel-like factor 12 (KLF12) via downregulation/methylation of miR-205; Acting as a competitive endogenous RNA or through epigenetic modification
03
Biological functions
Regulation of gene expression at the epigenetic and post-transcriptional levelRegulation of cell proliferationPotential modulation of DNA methylation (specifically, methylation of microRNA genes such as miR-205)Oncogenic activity in specific cancers such as osteosarcoma and bladder cancer
04
Disease associations
Cancer (implicated in osteosarcoma, bladder cancer, and potentially other malignancies)Other (investigated in the context of cell cycle progression)
05
Safety considerations
Not established, as there are no drugs clinically targeting ELF3-AS1 currently; potential therapeutic targeting may have off-target or epigenetic toxicity concerns (speculative, based on lncRNA function).
06
Biomarkers
Overexpression of ELF3-AS1 may serve as a biomarker for: Poor prognosis or aggressive disease in osteosarcomaProgression in bladder cancer
Beyond the preview
Go deeper on ELF3 antisense RNA 1 (ELF3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELF3 antisense RNA 1 (ELF3-AS1).